Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBQ5OL)

Drug Name
VIP-152 Drug Info
Synonyms
Enitociclib; 1255AT22ZJ; UNII-1255AT22ZJ; VIP152; CHEMBL4762845; VIP-152; BAY-1251152; 1610408-97-3; 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-(4-(((S(S))-S-methylsulfonimidoyl)methyl)-2-pyridinyl)-; 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[[[S(S)]-S-methylsulfonimidoyl]methyl]-2-pyridinyl]-; ENITOCICLIB [INN]; ENITOCICLIB [USAN]; GTPL11686; GLXC-26844; BDBM50556034; BAY 1251152; csc(S)-[(2-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}pyridin-4-yl)methyl](imino)(methyl)-l6-sulfanone
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
PubChem CID
139593425
TTD Drug ID
DMBQ5OL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Cyclin-dependent kinase 9 (CDK9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [3]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [4]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [5]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [7]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [3]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [3]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [9]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04978779) An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome. U.S.National Institutes of Health.
2 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
5 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
6 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
7 Clinical pipeline report, company report or official report of BioTheryX.
8 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
9 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
10 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.